论文部分内容阅读
美国两家生物技术公司于1984年分别克隆了因子Ⅶ后,各自与制药厂合资生产出足量的重组因子Ⅷ,从而可对其生物学特性进行广泛的体外鉴定,并在以后对血友病患者进行临床试验。
After the two biotech companies in the United States cloned Factor VII in 1984, each of them produced a large amount of recombinant factor VIII together with the pharmaceutical factory to conduct a wide range of in vitro identification of its biological characteristics. Afterwards, Patients undergo clinical trials.